Skip to main content

Table 1 Patients' characteristicsa

From: Quantification and clinical relevance of gene amplification at chromosome 17q12-q21 in human epidermal growth factor receptor 2-amplified breast cancers

Characteristic

Number of patients (%)

(n = 86)

Age, yr

 

   <50

33 (38.4%)

   ≥50

53 (61.6%)

T

 

   1

35 (40.7%)

   2

46 (53.5%)

   3

4 (4.6%)

   4

1 (1.2%)

N

 

   N+

51 (59.3%)

   N-

35 (40.7%)

SBR

 

   2

36 (42.3%)

   3

49 (57.7%)

   Missing

1

Hormone receptor status

 

   ER

 

ER-

60 (69.8%)

ER+

26 (30.2%)

   PR

 

PR-

44 (51.2%)

PR+

42 (48.8%)

   ER/PR

 

ER-/PR-

42 (48.9%)

ER-/PR+

18 (20.9%)

ER+/PR-

2 (2.3%)

ER+/PR+

24 (27.9%)

Treatment

 

   Chemotherapy

 

Anthracyclines

42 (48.8%)

Anthracyclines and taxanes

26 (30.2%)

No chemotherapy

18 (21.0%)

   Radiation therapy

86 (100.0%)

   Antihormone therapy

34 (39.5%)

   Trastuzumab

20 (23.3%)

Outcomes

 

Recurrence

25 (29.1%)

Death

17 (20.0%)

  1. aT, tumor size; N, lymph node status; SBR, Scarff-Bloom-Richardson histological grade; ER, estrogen receptor; PR, progesterone receptor.
Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us